A speech prosthetic developed by a collaborative team of Duke neuroscientists, neurosurgeons, and engineers can translate a person’s brain signals into what they’re trying to say.
Maples Scientific Publisher brings together the best original research, analyses, reviews, news updates, practice updates, and thought-provoking editorials.
New light activated cancer treatment.
Several antibodies and antibody fragments have been previously developed for the treatment of various diseases, including cancer3,4. These antibodies bind to cell surface receptors expressed at higher levels on cancer cells, addressing a major challenge of selective cell targeting in cancer therapy. Although full-length antibodies have shown promise for treatment of several cancers, limited success has been demonstrated in eliminating solid tumors. Due to their large size, full-length antibodies are unable to diffuse deep into solid tumors5. In addition, it has been shown that high-affinity antibodies bind to the periphery of the tumor tissues, forming a barrier and preventing their further penetration6. Some studies in patients with cancer estimate that only 0.01% of the injected antibodies accumulate per gram of solid tumor tissue7. Small antibody fragments with low molecular weight can diffuse much deeper into tissues, presenting an excellent alternative to full-length antibodies. However, small antibody fragments have a low residence time in the body and often have a higher rate of dissociation (koff) from the target compared with full-length antibodies, limiting their clinical utility8. To address these challenges, antibody fragments are often multimerized9,10 and/or conjugated to larger proteins11, which increases the size of antibody fragments, again reducing their ability to penetrate into the tumor.
One solution to overcome the limitation of low residence time would be to replace the noncovalent interactions between the antibody fragment and its antigen with a covalent bond. In a notable effort, an affibody containing a photocrosslinker in its antigen binding region was shown to covalently link to its antigen and demonstrated higher accumulation on tumor tissues12. Another pioneering study involved developing affibodies containing a latent bioreactive amino acid in their antigen binding region that forms a covalent bond with the target antigen by proximity-dependent reaction without any external impetus13. However, the former had substantially lower binding affinity compared with its wild-type (wt) counterpart and thus, requires using a high concentration for efficient initial binding, while the latter could react with target antigen expressed on healthy cells causing side effects.
This is a nontoxic version of cancer treatment that works on any type of cancer.
Breast cancer is the most common cancer affecting women in Singapore. Treatment is multimodal and often involves surgery to remove the cancer and lymph nodes involved.
Adjuvant therapy, given after the initial treatment, is used to irradiate and destroy micrometastases, which are cancer cells in the blood stream or lymphatics, to decrease recurrence. This form of therapy is subdivided into local (radiotherapy) and systemic therapy (endocrine therapy, chemotherapy and targeted therapy).
Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD
Discount Links:
Epigenetic, Telomere Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7xyIU-LSYLyQdQ6…M0&irgwc=1
Use Code: CONQUERAGING
Continue reading “Epigenetic Test #9: Finally, A Younger Horvath Age Than the Chronological” »
The original definition of the chosen word is to “seem to see, hear, feel, or smell” something that does not exist, usually because of “a health condition or because you have taken a drug”
The psychological verb gained an extra meaning in 2023 that ‘gets to the heart of why people are talking about artificial intelligence’
Protein indicators of subclinical peripheral heath in plasma were linked with markers of Alzheimer’s disease and neurodegeneration, cross-sectional proteomic analyses showed.
Greater protein-based risk for cardiovascular disease, heart failure mortality, and kidney disease was associated with plasma biomarkers of amyloid-beta, phosphorylated tau181 (p-tau181), neurofilament light (NfL, a measure of neuronal injury), and glial fibrillary acidic protein (GFAP, a measure of astrogliosis), even in people without cardiovascular or kidney disease, reported Keenan Walker, PhD, of the National Institute on Aging in Baltimore, and co-authors.
Proteomic indicators of body fat percentage, lean body mass, and visceral fat also were tied to p-tau181, NfL, and GFAP, Walker and colleagues wrote in the Annals of Neurology.
The sleep-wake cycle is among the most well-known circadian rhythms in the body and is severely affected in Alzheimer’s disease (AD). “Eighty percent of patients with AD suffer dysregulation or disruption of circadian rhythms, and the obvious clinical manifestations are the sleep-wake reversals,” Desplats said. “These patients are very sleepy during the day, agitated during the night, more confused, and sometimes aggressive.”
The feeding-fasting cycle is one of the strongest signals you can send the body to entrain the circadian clock.-Paula Desplats, University of California, San Diego
In a recent study published in Cell Metabolism, Desplats’s team used mice that are genetically engineered to develop AD to test whether intermittent fasting improves circadian rhythm abnormalities.3 Rather than restricting calories or making dietary changes, they simply limited food access to a defined six-hour daily window. They found that time-restricted eating improved sleep, metabolism, memory, and cognition, and reduced brain amyloid deposits and neuroinflammatory gene expression. “Many of the genes that are affected in AD are rhythmically expressed in the brain, meaning that they are in direct relation with the circadian clock and are involved in functions that are fundamental to AD pathology,” Desplats said. Intermittent fasting restored the rhythmic activity of these genes, but the real surprise was the extent to which it mitigated brain amyloid deposits and improved cognition and sleep-wake behaviors. “I didn’t expect that it will have such a dramatic impact on pathology,” Desplats said.
The regulation of genetic diversity resulting from polyploidization and its impact on environmental adaptability remain unclear. Here, the authors show that
To get several of the modified chromosomes into the same yeast cell, Boeke’s team ran a lengthy cross-breeding program, mating cells with different combinations of genomes. At each step there was an extensive “debugging” process, as synthetic chromosomes interacted in unpredictable ways.
Using this approach, the team incorporated six full chromosomes and part of another one into a cell that survived and grew. They then developed a method called chromosome substitution to transfer the largest yeast chromosome from a donor cell, bumping the total to seven and a half and increasing the total amount of synthetic DNA to over 50 percent.
Getting all 17 synthetic chromosomes into a single cell will require considerable extra work, but crossing the halfway point is a significant achievement. And if the team can create yeast with a fully synthetic genome, it will mark a step change in our ability to manipulate the code of life.
